VMQ StocksFor the value investor looking to harness academic research in
an actively managed portfolio
Bits and BipsNewsletter delivering insights on linking traditional finance, macro trends and cryptocurrency opportunities to help investors build stronger, more diversified portfolios.
All premium products come with free basic membership.
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Prelude Therapeutics Incorporated's fiscal Q4 earnings report was released on Monday, November 16. Let's dive in to see if (PRLD) missed or beat analyst's expectations.
As of Friday, November 13, Prelude Therapeutics Incorporated’s PRLD share price has dipped by
6.53%, which has investors questioning if this is right time to buy.
As of Thursday, November 12, Prelude Therapeutics Incorporated’s PRLD share price has dipped by
6.88%, which has investors questioning if this is right time to buy.
As of Wednesday, November 11, Prelude Therapeutics Incorporated’s PRLD share price has surged by
8.24%, which has investors questioning if this is right time to sell.
As of Monday, November 09, Prelude Therapeutics Incorporated’s PRLD share price has surged by
6.67%, which has investors questioning if this is right time to sell.
Tudor Pop
Financial Summary
Share Statistics
PRLD
Industry Median
Percentile (All Stocks)
Market Cap (Mil)
$336.1
$212.8
35%
Shares Out (Mil)
104.5
55.2
62%
Institutional Ownership
83.6%
93.3%
51%
Float (Mil)
22.3
40.8
30%
Beta
1.19
1.03
69%
Avg Daily Volume (000s)
271
559
49%
Price Change (52-week)
93.8%
40.3%
95%
Growth
PRLD
Industry Median
Percentile (All Stocks)
Sales (5yr)
na
13.6%
na
Net Income (5yr)
(11.8%)
(10.5%)
28%
EPS (5yr)
22.3%
15.4%
72
Dividends (5yr)
na
0.0%
0%
Cash Flow (5yr)
(55.1%)
(15.7%)
6%
Estimates
Qtrly
Current Fiscal Year
Next Fiscal Year
# of Estimates
4
4
5
Current EPS
($0.138)
($0.528)
($0.456)
Month Ago EPS
($0.152)
($0.567)
($0.580)
# Rev Up
1
1
0
# Rev Down
0
0
1
Three Months Ago EPS
($0.140)
($0.540)
($0.750)
Year/Year Chg
15.0%
(59.2%)
(89.1%)
Financials
PRLD
Industry Median
Percentile (All Stocks)
Sales (TTM) (Mil)
$22
$40
13%
Net Income (TTM) (Mil)
($53)
($44)
15%
EPS (TTM)
($0.588)
($1.400)
25%
Operating Cash Flow (TTM) (Mil)
($28)
($34)
13%
Net Cash Flow (TTM) (Mil)
($25)
$-0
27%
Long-Term Debt (Q1) (Mil)
$15
$4
31%
Enterprise Value (Q1) (Mil)
$230
$142
28%
Valuation
PRLD
Industry Median
Percentile (All Stocks)
P/B
2.71
1.97
67%
P/E
na
16.8
na
Dividend Yield
0.0%
0.0%
0%
PEG (5yr hist)
na
0.8
na
Ratios
PRLD
Industry Median
Percentile (All Stocks)
Gross Margin
100.0%
67.6%
96%
Net Margin
(247.1%)
(50.8%)
4%
ROA
(39.5%)
(47.4%)
13%
ROE
(58.4%)
(51.4%)
14%
Liabilities to Assets
29.3%
29.6%
20%
F-Score
3
3
18%
Prelude Therapeutics Incorporated did not pass any screens on 11/19/2026.
Looking for access to this powerful feature? Take the first step in becoming an A+ Investor today.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors